| A clinician's guide to X‐linked hypophosphatemia TO Carpenter, EA Imel, IA Holm, SM Jan de Beur, KL Insogna Journal of Bone and Mineral Research 26 (7), 1381-1388, 2011 | 670 | 2011 |
| A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis S Ichikawa, EA Imel, ML Kreiter, X Yu, DS Mackenzie, AH Sorenson, ... The Journal of clinical investigation 117 (9), 2684-2691, 2007 | 534 | 2007 |
| Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects Y Yamazaki, A Imura, I Urakawa, T Shimada, J Murakami, Y Aono, ... Biochemical and biophysical research communications 398 (3), 513-518, 2010 | 500 | 2010 |
| Burosumab therapy in children with X-linked hypophosphatemia TO Carpenter, MP Whyte, EA Imel, AM Boot, W Högler, A Linglart, ... New England Journal of Medicine 378 (21), 1987-1998, 2018 | 435 | 2018 |
| Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia TO Carpenter, EA Imel, MD Ruppe, TJ Weber, MA Klausner, ... The Journal of clinical investigation 124 (4), 1587-1597, 2014 | 326 | 2014 |
| Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial EA Imel, FH Glorieux, MP Whyte, CF Munns, LM Ward, O Nilsson, ... The Lancet 393 (10189), 2416-2427, 2019 | 313 | 2019 |
| Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans EA Imel, M Peacock, AK Gray, LR Padgett, SL Hui, MJ Econs The Journal of Clinical Endocrinology & Metabolism 96 (11), 3541-3549, 2011 | 284 | 2011 |
| A randomized, double‐blind, placebo‐controlled, phase 3 trial evaluating the efficacy of burosumab, an anti‐FGF23 antibody, in adults with X‐linked hypophosphatemia: week 24 … KL Insogna, K Briot, EA Imel, P Kamenický, MD Ruppe, AA Portale, ... Journal of Bone and Mineral Research 33 (8), 1383-1393, 2018 | 279 | 2018 |
| Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia EA Imel, M Peacock, P Pitukcheewanont, HJ Heller, LM Ward, D Shulman, ... The Journal of Clinical Endocrinology & Metabolism 91 (6), 2055-2061, 2006 | 246 | 2006 |
| Approach to the hypophosphatemic patient EA Imel, MJ Econs The Journal of Clinical Endocrinology & Metabolism 97 (3), 696-706, 2012 | 234 | 2012 |
| Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials M Wolf, J Rubin, M Achebe, MJ Econs, M Peacock, EA Imel, LL Thomsen, ... Jama 323 (5), 432-443, 2020 | 209 | 2020 |
| Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations EA Imel, LA DiMeglio, SL Hui, TO Carpenter, MJ Econs The Journal of Clinical Endocrinology & Metabolism 95 (4), 1846-1850, 2010 | 177 | 2010 |
| FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets EA Imel, SL Hui, MJ Ecibs Journal of Bone and Mineral Research 22 (4), 520-526, 2007 | 174 | 2007 |
| The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey A Skrinar, M Dvorak-Ewell, A Evins, C Macica, A Linglart, EA Imel, ... Journal of the Endocrine Society 3 (7), 1321-1334, 2019 | 170 | 2019 |
| Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23 EA Imel, X Zhang, MD Ruppe, TJ Weber, MA Klausner, T Ito, M Vergeire, ... The Journal of Clinical Endocrinology & Metabolism 100 (7), 2565-2573, 2015 | 161 | 2015 |
| Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial MP Whyte, TO Carpenter, GS Gottesman, M Mao, A Skrinar, J San Martin, ... The lancet Diabetes & endocrinology 7 (3), 189-199, 2019 | 152 | 2019 |
| Intronic Deletions in the SLC34A3 Gene Cause Hereditary Hypophosphatemic Rickets with Hypercalciuria S Ichikawa, AH Sorenson, EA Imel, NE Friedman, JM Gertner, MJ Econs The Journal of Clinical Endocrinology & Metabolism 91 (10), 4022-4027, 2006 | 136 | 2006 |
| Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo … AA Portale, TO Carpenter, ML Brandi, K Briot, HII Cheong, M Cohen-Solal, ... Calcified tissue international 105, 271-284, 2019 | 131 | 2019 |
| Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations S Ichikawa, G Baujat, A Seyahi, AG Garoufali, EA Imel, LR Padgett, ... American journal of medical genetics Part A 152 (4), 896-903, 2010 | 117 | 2010 |
| Fibroblast growth factor 23: roles in health and disease EA Imel, MJ Econs Journal of the American Society of Nephrology 16 (9), 2565-2575, 2005 | 112 | 2005 |
Wolfgang HöglerJohannes Kepler University, Linz and University of Birmingham在 jku.at 的电子邮件经过验证
